Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
← catalyst calendarNCT06500273 · readout ≤ 498 d
Sponsored by Allogene Therapeutics (industry) · ALLO — their whole pipeline →. With Foresight Diagnostics, Inc., Natera, Inc..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
250estimated
Sites
82
Countries
Australia, Canada, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-18 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Large B-cell Lymphoma
Interventions
- Genetic: cemacabtagene ansegedleucel — also filed as cema-cel
- Drug: Fludarabine — also filed as Fludara®
- Drug: Cyclophosphamide — also filed as Cytoxan®
- Device: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™ — also filed as Foresight Lymphoma MRD Therapy Selection Test
Primary outcome
what the primary-completion date above is the date OFEvent-free survival per independent review committee assessment
measured Up to 60 months
Permalink · ALLO's whole pipeline · Catalyst calendar · Every registered study · What changed